Screener
4D Molecular Therapeutics FDMT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Issuance of common stock upon exercise of stock options | 1,674 | — |
| Issuance of common stock under the ATM offering program, net of issuance costs | 9,810 | — |
| Net cash provided by financing activities | 11,484 | — |
| Net increase (decrease) in cash and cash equivalents | 12,247 | (15,810) |
| Cash and cash equivalents, beginning of period | 60,241 | 149,336 |
| Cash and cash equivalents, end of period | $72,488 | $133,526 |
| Supplemental disclosures of noncash investing and financing information | ||
| Purchases of property and equipment in accounts payable and accrued and other liabilities | — | $140 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's net change in cash?
- 4D Molecular Therapeutics (FDMT) reported net change in cash of $12.25M in Q1 2026.
- How has 4D Molecular Therapeutics's net change in cash changed year-over-year?
- 4D Molecular Therapeutics's net change in cash increased by 177.5% year-over-year, from -$15.81M to $12.25M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about 4D Molecular Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude